Cantabio Pharmaceuticals Inc. has been awarded a grant by The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to support the development of a cell-penetrant DJ-1 protein replacement therapeutic candidate for the treatment of Parkinson’s disease.

The Foundation for the National Institutes of Health (FNIH) has announced the online publication of the first playbook designed to help accelerate the development of adeno-associated virus (AAV) gene therapies for rare diseases.

Aprea Therapeutics Inc. has submitted an IND application to the FDA to initiate clinical trials of APR-1051, an oral next-generation small-molecule inhibitor of WEE1 kinase.

Halia Therapeutics Inc. and Canary Speech Inc. have established a collaboration in Alzheimer’s disease.

Aatec Medical GmbH has announced the start of its collaboration with the German Federal Agency for Disruptive Innovations (SPRIND), which will help advance the preclinical development of ATL-105.

At the ongoing WORLDSymposium meeting in San Diego, Gain Therapeutics Inc. presented preclinical data on the company’s GCase enhancer GT-02287 as a potential approach to rescue motor function in Parkinson’s disease (PD).